Statera Biopharma, Inc. (CBLI) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Net income	-101.9	-12.1	-2.6	-3.6	-9.7	-2.7	-12.6	1.6
Depreciation and amortization [+]	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.8
Depreciation	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2
Amortization of intangible assets							0.1	0.6
Asset impairment charges	67.6
Stock-based compensation	6.1	2.7				0.0	0.1	0.5
Change in working capital [+]	1.5	-0.1	0.8	0.7	-1.2	0.8	1.9	6.3
Accounts receivable	-0.4				-0.1	0.3	-0.4	0.6
Other current assets	0.9	-0.3				0.2	-0.3	0.0
Accounts payable					-1.0	0.1	-0.8	0.5
Accrued expenses						0.2	0.2	0.2
Deferred revenues	0.4					0.0	-0.1	-0.8
Other	0.5	0.3	0.8	0.7			3.3	5.7
Other operating activities	-1.5	4.4	-0.8	-1.7	4.2	-3.2	-1.7	-23.7
Cash from operations	-28.2	-5.1	-2.7	-4.6	-6.6	-5.0	-12.1	-14.5

Capital expenditures [+]	-0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchases of property and equipment	-0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Sales of property and equipment			0.1	0.0	0.0	0.2	0.0
Sales of short-term investments, net [+]			1.4	11.7	12.5			0.3
Purchases of short-term investments								-1.4
Sales of short-term investments			1.4	11.7	12.5			1.7
Other cash from investing	13.6		-1.2	-7.7	-8.6	5.5	-10.3	-2.0
Cash from investing	13.5	0.0	0.2	4.0	3.9	5.7	-10.3	-1.8

Issuance of common stock, net	7.3						28.1	9.7
Financing costs	-0.3
Other cash from financing	13.3	5.7		0.1		0.5	-3.2
Cash from financing	21.0	5.7	0.0	0.1	0.0	0.5	24.9	10.6

Free cash flow	-28.4	-5.1	-2.7	-4.6	-6.6	-5.0	-12.1	-14.5
Per share (diluted)	($0.81)	($0.70)	($0.24)	($0.41)	($0.59)	($0.46)	($1.71)	($5.36)

Cash paid for interest	1.3						0.5	0.5